599,195 Shares in Monopar Therapeutics Inc. (NASDAQ:MNPR) Bought by Adage Capital Partners GP L.L.C.

Adage Capital Partners GP L.L.C. bought a new stake in shares of Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 599,195 shares of the company's stock, valued at approximately $13,182,000. Adage Capital Partners GP L.L.C. owned 9.82% of Monopar Therapeutics as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. JPMorgan Chase & Co. acquired a new position in Monopar Therapeutics during the 4th quarter worth $45,000. Geode Capital Management LLC boosted its stake in Monopar Therapeutics by 174.4% during the 4th quarter. Geode Capital Management LLC now owns 38,596 shares of the company's stock valued at $849,000 after purchasing an additional 24,530 shares in the last quarter. Finally, ADAR1 Capital Management LLC bought a new stake in shares of Monopar Therapeutics in the 4th quarter worth $2,861,000. Institutional investors and hedge funds own 1.83% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Jones Trading reissued a "hold" rating on shares of Monopar Therapeutics in a report on Wednesday, April 2nd. HC Wainwright reissued a "buy" rating and set a $40.00 price objective on shares of Monopar Therapeutics in a research note on Tuesday, April 1st. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $76.00 target price on shares of Monopar Therapeutics in a report on Wednesday, March 19th.

Insider Buying and Selling

In related news, major shareholder Tactic Pharma Llc sold 33,334 shares of the company's stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $35.00, for a total transaction of $1,166,690.00. Following the completion of the sale, the insider now directly owns 822,255 shares of the company's stock, valued at approximately $28,778,925. This represents a 3.90 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 34.90% of the company's stock.

Monopar Therapeutics Stock Performance

Shares of NASDAQ MNPR traded down $0.14 during mid-day trading on Wednesday, reaching $41.82. The company had a trading volume of 13,898 shares, compared to its average volume of 359,022. The stock has a market capitalization of $255.65 million, a PE ratio of -21.23 and a beta of 1.01. Monopar Therapeutics Inc. has a twelve month low of $1.72 and a twelve month high of $54.30. The stock's 50 day moving average is $35.47 and its 200-day moving average is $29.14.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its quarterly earnings results on Monday, March 31st. The company reported ($2.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($1.87). On average, sell-side analysts anticipate that Monopar Therapeutics Inc. will post -1.65 EPS for the current year.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.